Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $16.00 target price on the biotechnology company’s stock.

A number of other equities analysts also recently commented on ATXS. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. TD Cowen began coverage on Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Down 7.1 %

Shares of Astria Therapeutics stock opened at $9.37 on Thursday. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The company has a 50 day moving average of $11.40 and a 200 day moving average of $10.62. The company has a market capitalization of $528.75 million, a P/E ratio of -4.48 and a beta of 0.71.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ATXS. Vanguard Group Inc. increased its position in Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares during the period. Ameritas Investment Partners Inc. grew its position in Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares during the last quarter. American International Group Inc. increased its stake in Astria Therapeutics by 49.4% in the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 8,122 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics in the first quarter valued at about $200,000. Finally, Tidal Investments LLC acquired a new stake in shares of Astria Therapeutics during the first quarter worth about $1,664,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.